Trial ID or NCT#

NCT00185965

Status

not recruiting iconNOT RECRUITING

Purpose

This is a single institution phase I / II trial to evaluate the safety, feasibility and efficacy of CpG injections (4 intratumoral injections followed by 6 peri-tumoral injections) combined with local irradiation in patients with recurrent low-grade lymphomas. Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 (2 Gy each day). CpG injections will be administered into the same tumor site within the 24 hours before and the 24 hours after the radiation, and on days 8 and 15. Weekly doses of CpG will be then administered subcutaneously in the region of previous injections for 6 additional doses.

Official Title

Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ronald Levy, MD
Ronald Levy, MD
Medical oncologist, Lymphoma specialist
Robert K. and Helen K. Summy Professor in the School of Medicine
Sandra Horning
Richard Hoppe
Richard Hoppe
Radiation oncologist
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Susan Knox
Susan Knox
Radiation oncologist
Associate Professor of Radiation Oncology, Emerita

Contact us to find out if this trial is right for you.

CONTACT

Cameron Harrison
(650) 721-7186